PRESS RELEASE published on 10/16/2023 at 12:30, 2 years 5 months ago Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/15/2023 at 12:30, 2 years 5 months ago Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/11/2023 at 12:30, 2 years 5 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
PRESS RELEASE published on 10/09/2023 at 22:01, 2 years 5 months ago Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 10/04/2023 at 12:30, 2 years 5 months ago Immunic to Participate in Scientific Conferences in October
PRESS RELEASE published on 09/06/2023 at 12:30, 2 years 6 months ago Immunic to Participate in Industry and Investor Conferences in September
PRESS RELEASE published on 08/17/2023 at 12:30, 2 years 7 months ago Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 08/01/2023 at 12:30, 2 years 7 months ago Immunic to Participate in Investor and Scientific Conferences in August
PRESS RELEASE published on 06/29/2023 at 12:30, 2 years 8 months ago Immunic to Participate in Scientific and Investor Conferences in July
PRESS RELEASE published on 05/30/2023 at 12:30, 2 years 9 months ago Immunic to Participate in Scientific and Investor Conferences in June
Published on 03/23/2026 at 08:00, 23 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 6 hours 23 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 08:00, 23 minutes ago Zentra Group plc: Unaudited interim report for the six months ended 31 December 2025
Published on 03/23/2026 at 08:00, 23 minutes ago Notification of the Greenshoe-Option and Stabilization Measures in accordance with Art. 5 (4)(b), (5) and (6) of Reg. (EU) 596/2014 and Art. 8 (f) and Art. 6 (3) Comm. Delegated Reg. (EU) 2016/1052
Published on 03/23/2026 at 07:46, 37 minutes ago Delivery Hero to sell Taiwan food delivery operations to Grab for USD 600 million
Published on 03/23/2026 at 07:30, 53 minutes ago Nordex Group receives new order from Serbia for 70 MW
Published on 03/20/2026 at 19:00, 2 days 13 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 14 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 2 days 15 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 14 hours ago Filing of the 2025 Universal Registration Document
